Christine Potkay

Christine Potkay is an associate in Goodwin’s Intellectual Property Litigation practice.

Christine has experience litigating patent and trademark matters in federal court and in proceedings before the United States Patent and Trademark Office and the International Trade Commission (ITC). Christine has represented clients in arbitration proceedings arising from intellectual property licenses and commercial agreements. Christine also maintains an active pro bono practice.

Christine has been involved in various stages of patent litigation, from pre-suit investigation through trial. Some of her engagements include:

• Representing Dr. Reddy’s Laboratories in litigation concerning its generic equivalent to Suboxone®, a product used to treat opioid use disorder
• Representing Teva in Hatch-Waxman litigation related to a generic version of a drug product for the treatment of ADHD
• Represented Civiq Smartscapes, LLC against claims of patent infringement relating to digital outdoor displays
• Represented Actavis Laboratories in Hatch-Waxman litigation concerning its generic equivalent to Minivelle®, an estradiol transdermal system

PRO BONO

Christine maintains an active pro bono practice, including working with the ACLU of Massachusetts and ACLU of Michigan to challenge policies and practices denying medication for the treatment of opioid use disorder (MOUD) to incarcerated people.

While attending law school, Christine was a judicial intern to the Honorable Jerome B. Simandle, U.S. District Judge for the District of New Jersey (Summer 2015) and the Honorable Michael A. Shipp, U.S. District Judge for the District of New Jersey (Spring 2017).

Christine is an editor of the Goodwin PTAB Trial Tracker periodic newsletter.

• Special Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S. 2023-2024 ed.,” published by Thomson Reuters, January 2024
• Special Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2022-2023 ed.,” published by Thomson Reuters, December 2022
• Special Contributor, "Guide to Biosimilars Litigation and Regulation in the U.S., 2021-2022 ed.," published by Thomson Reuters, October 2022
• Special Contributor, "Guide to Biosimilars Litigation and Regulation in the U.S., 2020-2021 ed.," published by Thomson Reuters, January 2021 
• Contributor, "Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.," published by Thomson Reuters, November 2019
• Co-Author, “Examining Octane Fitness Five Years On,” IP Watchdog, April 2019